ARTMS has entered into a tri-party co-operation with fellow industry leaders, POINT Biopharma and the Canadian Molecular Imaging Probe Consortium (CanProbe), a joint venture between the Centre for Probe Development...
Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models. Initiation of a Phase 1 therapeutic clinical trial planned for 1H2022
25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria, Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21.
Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa
Northstar Medical Radioisotopes and POINT Biopharma today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).